Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2010 (2010), Article ID 969383, 6 pages
http://dx.doi.org/10.1155/2010/969383
Clinical Study

Serum Endoglin Levels in Patients Suffering from Systemic Sclerosis and Elevated Systolic Pulmonary Arterial Pressure

1Rheumatology Section, Fundación Santa Fe de Bogotá, School Medicine Universidad de los Andes, Bogotá, Colombia
2Rheumatology Unit, Universidad Nacional de Colombia, Bogotá, Colombia
3Biochemistry Unit, Universidad Nacional de Colombia, Bogotá, Colombia

Received 16 April 2010; Revised 11 June 2010; Accepted 20 July 2010

Academic Editor: Lorinda Chung

Copyright © 2010 Paola Ximena Coral-Alvarado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. C. LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Google Scholar · View at Scopus
  2. M. B. Kahaleh, “The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy),” Clinical and Experimental Rheumatology, vol. 10, supplement 7, pp. 51–56, 1992. View at Google Scholar · View at Scopus
  3. M. B. Kahaleh, “Vascular involvement in systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 22, supplement 33, pp. S19–S23, 2004. View at Google Scholar · View at Scopus
  4. C. P. Denton and D. J. Abraham, “Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis,” Current Opinion in Rheumatology, vol. 13, no. 6, pp. 505–511, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Ihn, “Pathogenesis of fibrosis: role of TGF-β and CTGF,” Current Opinion in Rheumatology, vol. 14, no. 6, pp. 681–685, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Leask, D. J. Abraham, D. R. Finlay et al., “Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts,” Arthritis and Rheumatism, vol. 46, no. 7, pp. 1857–1865, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Dharmapatni, M. D. Smith, M. J. Ahern et al., “The TGF β receptor endoglin in systemic sclerosis,” Asian Pacific Journal of Allergy and Immunology, vol. 19, no. 4, pp. 275–282, 2001. View at Google Scholar · View at Scopus
  8. C. P. Denton and C. M. Black, “Pulmonary hypertension in systemic sclerosis,” Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 335–349, 2003. View at Google Scholar · View at Scopus
  9. J. G. Coghlan and D. Mukerjee, “The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology,” Current Opinion in Rheumatology, vol. 13, no. 6, pp. 495–499, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. F. M. Wigley, J. A. C. Lima, M. Mayes, D. McLain, J. L. Chapin, and C. Ward-Able, “The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists,” Arthritis and Rheumatism, vol. 52, no. 7, pp. 2125–2132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Simon, R. Gibbs, and T. W. Higenbottam, “Recommendations on the management of pulmonary hypertension in clinical practice,” Heart, vol. 86, supplement 1, pp. I1–I3, 2001. View at Google Scholar
  12. “Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee,” Arthritis and Rheum, vol. 23, pp. 581–590, 1980. View at Scopus
  13. R. W. Battle, M. A. Davitt, S. M. Cooper et al., “Prevalence of pulmonary hypertension in limited and diffuse scleroderma,” Chest, vol. 110, no. 6, pp. 1515–1519, 1996. View at Google Scholar · View at Scopus
  14. D. Mukerjee, D. St George, B. Coleiro et al., “Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach,” Annals of the Rheumatic Diseases, vol. 62, no. 11, pp. 1088–1093, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Clements, P. A. Lachenbruch, J. R. Seibold et al., “Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies,” Journal of Rheumatology, vol. 20, no. 11, pp. 1892–1896, 1993. View at Google Scholar · View at Scopus
  16. C. P. Denton and C. M. Black, “Pulmonary hypertension in systemic sclerosis,” Rheumatic Disease Clinics of North America, vol. 29, no. 2, pp. 335–349, 2003. View at Google Scholar · View at Scopus
  17. J. Wipff, A. Kahan, E. Hachulla et al., “Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension,” Rheumatology, vol. 46, no. 4, pp. 622–625, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Gougos and M. Letarte, “Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line,” Journal of Immunology, vol. 141, no. 6, pp. 1925–1933, 1988. View at Google Scholar · View at Scopus
  19. W. L. Parker, M. B. Goldring, and A. Philip, “Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFβ receptor independent manner,” Journal of Bone and Mineral Research, vol. 18, no. 2, pp. 289–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Gougos, S. St Jacques, A. Greaves et al., “Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts,” International Immunology, vol. 4, no. 1, pp. 83–92, 1992. View at Google Scholar · View at Scopus
  21. P. Lastres, C. Cabanas, T. Bellon et al., “Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen,” European Journal of Immunology, vol. 22, no. 2, pp. 393–397, 1992. View at Google Scholar · View at Scopus
  22. H.-J. Buhring, C. A. Muller, M. Letarte et al., “Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow,” Leukemia, vol. 5, no. 10, pp. 841–847, 1991. View at Google Scholar · View at Scopus
  23. C.-Z. Chen, M. Li, D. De Graaf et al., “Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15468–15473, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. D. Blann, J. M. Wang, P. B. Wilson, and S. Kumar, “Serum levels of the TGF-beta receptor are increased in atherosclerosis,” Atherosclerosis, vol. 120, no. 1-2, pp. 221–226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Li, B. Guo, P. B. Wilson et al., “Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer,” International Journal of Cancer, vol. 89, no. 3, pp. 122–126, 2000. View at Google Scholar · View at Scopus
  26. N. Takahashi, R. Kawanishi-Tabata, A. Haba et al., “Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin,” Clinical Cancer Research, vol. 7, no. 3, pp. 524–532, 2001. View at Google Scholar · View at Scopus
  27. L. Calabrò, E. Fonsatti, G. Bellomo et al., “Differential levels of soluble endoglin (CD105) in myeloid malignancies,” Journal of Cellular Physiology, vol. 194, no. 2, pp. 171–175, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. H. F. C. Rulo, J. R. Westphal, P. C. M. Van De Kerkhof, R. M. W. De Waal, I. M. J. J. Van Vlijmen, and D. J. Ruiter, “Expression of endoglin in psoriatic involved and uninvolved skin,” Journal of Dermatological Science, vol. 10, no. 2, pp. 103–109, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. K. A. McAllister, K. M. Grogg, D. W. Johnson et al., “Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1,” Nature Genetics, vol. 8, no. 4, pp. 345–351, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Fujimoto, M. Hasegawa, Y. Hamaguchi et al., “A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease,” Dermatology, vol. 213, no. 2, pp. 88–92, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wipff, J. Avouac, D. Borderie et al., “Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin,” Rheumatology, vol. 47, no. 7, pp. 972–975, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Coral-Alvarado, G. Quintana, M. F. Garces et al., “Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis,” Rheumatology International, vol. 29, no. 9, pp. 1017–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Amanzi, F. Braschi, G. Fiori et al., “Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions,” Rheumatology, vol. 49, no. 7, pp. 1374–1382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. J. Cepeda and J. D. Reveille, “Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance,” Current Opinion in Rheumatology, vol. 16, no. 6, pp. 723–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Coral-Alvarado, A. Rojas-Villarraga, M. C. Latorre et al., “Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: review of the literature,” Journal of Rheumatology, vol. 35, no. 2, pp. 244–250, 2008. View at Google Scholar · View at Scopus
  36. G. M. Mitri, M. Lucas, N. Fertig, V. D. Steen, and T. A. Medsger Jr., “A comparison between anti-TH/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 203–209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Sulli, M. Ghio, G. P. Bezante et al., “Blunted coronary flow reserve in systemic sclerosis,” Rheumatology, vol. 43, no. 4, pp. 505–509, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. R. J. Barst, M. McGoon, A. Torbicki et al., “Diagnosis and differential assessment of pulmonary arterial hypertension,” Journal of the American College of Cardiology, vol. 43, no. 12, pp. 40S–47S, 2004. View at Publisher · View at Google Scholar · View at Scopus